If you've ever tried everything — dieting, cardio, strength training — and still can't seem to move the fat around your belly, hips, or thighs, you're not alone. These "stubborn" fat deposits are notoriously resistant to lifestyle changes alone. AOD 9604 is a peptide specifically researched for this problem: it turns on fat-burning without many of the side effects associated with full human growth hormone therapy.
Here's what it is, how it works, and who it's designed for.
What Is AOD 9604?
AOD 9604 (Anti-Obesity Drug 9604) is a synthetic fragment of the C-terminus of human growth hormone (HGH) — specifically amino acids 176–191. Scientists discovered that this short region of the HGH molecule is responsible for HGH's fat-burning (lipolytic) activity, while the rest of the molecule handles growth and IGF-1 stimulation.
By isolating this fragment, researchers created a peptide that could potentially replicate HGH's effect on fat breakdown without increasing IGF-1 levels, stimulating growth, or affecting blood sugar — all of which are concerns with full HGH therapy.
AOD 9604 is not HGH. It's a small piece of the HGH molecule — the part that tells your body to break down fat — without the growth-promoting effects that make full HGH therapy complex and risky.
How AOD 9604 Works
AOD 9604 works through two primary mechanisms:
- Lipolysis stimulation: It activates the breakdown of stored fat cells, particularly visceral and subcutaneous fat in stubborn areas.
- Lipogenesis inhibition: It reduces the formation of new fat tissue, preventing your body from storing new fat as efficiently.
Unlike full HGH, AOD 9604 does not bind to the IGF-1 receptor, does not stimulate insulin-like growth factor production, and has not been shown to raise blood glucose. This favorable safety profile led the FDA to grant it GRAS (Generally Recognized as Safe) status for use in food products, and it was studied in Phase 2 obesity trials in the early 2000s.
What AOD 9604 Is Used For
Stubborn Body Fat
Belly, hips, thighs — areas resistant to diet and exercise.
Weight Loss Plateau
When calorie restriction has stopped producing results.
GLP-1 Stack Add-On
Pairs with semaglutide or tirzepatide to enhance fat oxidation.
Cartilage Support
Some research suggests benefit for joint and cartilage repair.
Who Is the Ideal Candidate?
AOD 9604 is best suited for people who:
- Are at or near their goal weight but have localized fat deposits that won't respond to diet
- Have BMI under 30 but struggle with body composition (fat-to-muscle ratio)
- Are already on a GLP-1 medication and want to amplify fat burning
- Want a milder, lower-risk alternative to full HGH therapy for body composition
It is not the primary choice for someone with significant weight to lose (30+ lbs). In that case, GLP-1 medications like semaglutide or tirzepatide produce far more dramatic results. AOD 9604 is more of a precision tool for the final 10–15 lbs or stubborn pockets of fat.
Stacking AOD 9604 with Semaglutide
One of the more clinically interesting applications is combining AOD 9604 with a GLP-1 agonist like semaglutide. The logic is straightforward: semaglutide reduces caloric intake and overall fat mass, while AOD 9604 specifically targets lipolysis (the release and burning of stored fat). They work through entirely different pathways and don't overlap in mechanism.
Some providers use this combination for patients who are in the later stages of a weight loss program — where they've lost significant weight but have stubborn areas remaining. The stack can also help preserve lean muscle while maximizing fat oxidation.
Dosing and Protocol
| Parameter | Details |
|---|---|
| Typical Dose | 250–500 mcg per day |
| Administration | Subcutaneous injection |
| Timing | 30–60 min before exercise or in the morning on an empty stomach |
| Cycle Length | 8–12 weeks, with a break |
| Stack Compatibility | Compatible with semaglutide, tirzepatide, CJC-1295/Ipamorelin |
Safety and Side Effects
AOD 9604 has a favorable safety profile in human trials. Because it doesn't elevate IGF-1 or affect blood glucose, many of the risks associated with full HGH therapy don't apply. Reported side effects are mild and may include:
- Mild injection site redness or swelling
- Occasional headache or fatigue, especially early in treatment
- Flushing (rare)
It has not shown carcinogenic effects in animal studies, and the FDA's GRAS designation reflects a strong safety data set at the doses studied.
Frequently Asked Questions
Will AOD 9604 help me build muscle?
No — AOD 9604 does not significantly stimulate muscle growth. It's a fat-targeting fragment. For muscle building alongside fat loss, a GH secretagogue stack like CJC-1295/Ipamorelin would be more appropriate.
How long before I see results?
Most patients report noticeable changes in body composition within 4–8 weeks, particularly in stubborn areas. Results are enhanced when combined with consistent exercise and adequate protein intake.
Does AOD 9604 require a prescription?
Yes. When obtained through a licensed U.S. telehealth provider, AOD 9604 is prescribed and dispensed through a licensed compounding pharmacy. Self-sourcing research chemicals carries significant quality and safety risks.
Is this the same as HGH?
No. AOD 9604 is a small fragment of the HGH molecule. It does not produce the growth-stimulating effects of full HGH, does not raise IGF-1, and does not require the same level of clinical monitoring.